I-Lenvatinib Mesylate Intermediate CAS 15568-85-1 Purity >97.0% (HPLC) Factory
I-Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
I-Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
I-Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
I-Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
I-Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
I-4-Amino-3-Chlorophenol CAS 17609-80-2
I-4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
I-Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igama Lekhemikhali | 5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione |
Omqondofana | 5-(Methoxymethylene) I-Meldrum's Acid;Ukungcola kwe-Cabozantinib 56;I-Lenvatinib Ukungcola 79 |
Inombolo ye-CAS | 15568-85-1 |
Inombolo yeCAT | I-RF-PI1967 |
Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani |
I-Molecular Formula | I-C8H10O5 |
Isisindo samangqamuzana | 186.16 |
I-Melting Point | 132.0~134.0℃ |
Ukuminyana | 1.297±0.06 g/cm3 |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | Impushana Ephuzi |
1 H NMR Spectrum | Ihambisana Nesakhiwo |
Ukuhlanzeka / Indlela Yokuhlaziya | >97.0% (HPLC) |
Ukungcola Okuphelele | <3.00% |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | I-Intermediate ye-Lenvatinib Mesylate (CAS: 857890-39-2) |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS:15568-85-1) iphakathi kwe-Lenvatinib Mesylate (CAS: 857890-39-2).I-Lenvatinib iyisidakamizwa somdlavuza we-thyroid esakhiwe yi-Eisai Corporation yaseJapane (Ikhodi: E7080), eyingxenye ye-inhibitor ye-oral multi-receptor tyrosine kinase (RTK) futhi ingavimbela umsebenzi we-kinase we-vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( I-FLT1), i-VEGFR2 (KDR), ne-VEGFR3 (FLT4).I-Lenvatinib ingaphinde ivimbele ukubandakanyeka kwamanye ama-RTK ku-angiogenesis ye-pathological, ukukhula kwesimila, nokuqhubeka komdlavuza ngaphandle kwemisebenzi yawo evamile yamaselula kuhlanganise ne-fibroblast growth factor (FGF) receptors FGFR1, 2, 3, kanye ne-4;i-platelet-derived growth factor receptor (PDGFR [alpha]), i-KIT, ne-RET.[Izinkomba]: I-Lenvatinib ifanelekela ukwelapha iziguli ezinomdlavuza wegilo wokuphindaphinda kwendawo noma uhlobo lwe-metastasis, uhlobo lwe-progressivity kanye nohlobo oluhlukanisiwe lwe-radioactive iodine-refractory.NgoFebhuwari 13, 2015, i-US FDA yagunyaza isidakamizwa esilwa nomdlavuza i-Lenvatinib sokwelapha umdlavuza wegilo.I-Lenvatinib iyi-multi-target enzyme inhibitor, ekwazi ukuvimbela i-VEGFR2 ne-VEGFR3 (i-vascular endothelial growth factor receptor).Igama lokuhweba le-Lenvatinib yi-Lenvima.Ngomhla zingama-20 kuNhlaba wezi-2015, i-European Medicines Agency (EMA) igunyaze i-Lenvatinib yokwelashwa komdlavuza wegilo wegilo (DTC) ohlaselayo, othuthuke kakhulu noma ometastatic (papillary, follicular, Hurthle type) thyroid cancer (DTC).Ocwaningweni, isikhathi esimaphakathi sokusinda kweziguli ezine-radioactive iodine-refractory DTC ezilashwe nge-Lenvatinib kwakuyizinyanga eziyi-18 kanti inani leziguli ezithatha i-placebo yizinyanga ezi-3 kuphela.